Linezolid Accord

Linezolid, the active ingredient in Linezolid Accord, is an oxazolidinone antibiotic presented as a tablet formulation for oral use. It treats infections caused by susceptible bacteria, including skin and soft‑tissue infections, community‑acquired and nosocomial pneumonia, and MRSA infections.

GNH USA supplies Linezolid Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linezolid is an oxazolidinone antibiotic that targets Gram‑positive bacterial infections. - Skin and soft tissue infections: eradicates susceptible organisms, including MRSA, improving wound healing. - Community‑acquired pneumonia: provides coverage against typical and atypical pathogens, aiding respiratory recovery. - Nosocomial pneumonia: active against resistant strains in hospital‑acquired lung infections. - Methicillin‑resistant Staphylococcus aureus (MRSA) infections: eliminates MRSA in skin, respiratory and other sites.

Linezolid may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, often self‑limiting. - Headache: transient cranial discomfort. - Metallic taste: altered taste perception. - Vomiting: occasional emesis. - Myelosuppression: reduction in blood cell counts.

Serious or Rare Side Effects: - Thrombocytopenia: significant drop in platelet count. - Peripheral neuropathy: nerve damage causing tingling or numbness. - Serotonin syndrome: risk when combined with serotonergic agents. - Lactic acidosis: rare metabolic disturbance. - Optic neuritis: vision changes requiring urgent attention. - Severe anemia: marked decrease in red blood cells.

Before prescribing Linezolid Accord, clinicians should consider several safety aspects. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Hematologic monitoring: perform regular complete blood counts during therapy. - Concomitant serotonergic agents: avoid due to risk of serotonin syndrome. - Pregnancy: category B; use only when benefit outweighs potential risk. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Linezolid can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): may cause hypertensive crisis. - Serotonergic agents (SSRIs, SNRIs, tramadol): risk of serotonin syndrome. - Rifampin: reduces linezolid plasma concentrations, decreasing efficacy.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase bleeding risk. - Warfarin: potential enhancement of anticoagulant effect. - Anticonvulsants (phenytoin, carbamazepine): possible reduction in linezolid levels.